AcelRx Pharma Announces Divestment Of DSUVIA - Quick Facts

AcelRx Pharmaceuticals, Inc. (ACRX) announced the divestment of its FDA-approved drug, DSUVIA to Alora Pharmaceuticals. The agreement provides AcelRx with a 15% royalty on commercial sales of DSUVIA, a 75% royalty on sales of DSUVIA to the Department of Defense, DSUVIA's single largest customer, and up to $116.5 million in sales-based milestones.

AcelRx Pharma said the divestment will allow for AcelRx to focus its operations and capital on its late stage, high-value asset programs, with specific prioritization of its lead nafamostat program, Niyad.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bloomington, Minnesota -based Hoyo, SBC is recalling around 1,046 pounds of ready-to-eat beef sambusa products citing possible foreign matter contamination, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recalled products may be contaminated with extraneous materials, specifically thin, wire-like metal. New York-based Mockingbird LLC has expanded its initial recall in November to now include about 25,390 units of single strollers citing risk for fall, the U.S. Consumer Product Safety Commission said. The company in November last year had recalled about 149,000 units of single-to-double strollers due to the same concern. First Republic Bank, the latest casualty in the ongoing banking turmoil, said it has secured around $30 billion funding from America's 11 largest banks as a lifeline, including JPMorgan Chase, Bank of America, Citigroup, and Wells Fargo. Following the news, the bank's stock, which has been sinking since last week, gained around 10% on Thursday from the previous day's close.
Follow RTT